Leveraging Machine Learning to Improve Risk Prediction for Chemotherapy Induced NeuropathyChemotherapy-associated peripheral neuropathy (CPN) affects nearly 70% of cancer patients. An estimated 30% of cancer survivors have persistent CPN, which can have a devastating impact on their quality of life and functioning. Our objective is to develop and validate a predictive model that will identify those patients who are at high risk of developing severe CPN that can result in their receiving fewer planned chemotherapy cycles. We will focus on two subgroups our preliminary studies suggest have a higher risk for CPN: people who have diabetes or are African American/ Black.
Investigator: Adams, Alyce; Neugebauer, Romain
Funder: National Cancer Institute